Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour FEV1 Profile of Olodaterol in COPD
NCT01040689Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2010
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Jan 2010; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01040689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01040689.